Corporate Partnerships

BGI is one of the world’s leading genomics institutions, internationally recognized for its advanced sequencing technologies and large-scale research capabilities. With state-of-the-art NGS (Next Generation Sequencing) platforms, BGI drives innovation in genetic testing, population genomics, and precision medicine. Through a strategic technological collaboration, Bioscience Institute integrates BGI’s NGS expertise to enhance the accuracy and depth of its genomic and prenatal testing services. This partnership ensures high-quality, reliable results supported by cutting-edge sequencing methodologies and global scientific standards.

Dubai Healthcare City (DHCC) is one of the leading medical hubs in the Middle East, bringing together hospitals, clinics, research centers, and world-class healthcare services. Located in the heart of Dubai, it offers a highly regulated environment focused on clinical excellence and innovation. Within this prestigious medical district, Bioscience Institute operates one of its key facilities, providing advanced diagnostic, regenerative, and genomic services. Our presence in DHCC ensures the highest standards of quality, safety, and international compliance for our patients and partners.

The University of Rome “Tor Vergata” is one of Italy’s leading academic and research institutions, internationally recognized for its excellence in biomedical sciences and clinical innovation. Within this scientific environment, Bioscience Institute collaborates through the university spin-off Bioscience Genomics, a partnership dedicated to advanced prenatal testing and cutting-edge genomic analysis. This collaboration strengthens research, validation, and technological development in the field of molecular diagnostics. Together, the two institutions contribute to high-quality genomic services built on scientific rigor and continuous innovation.

Harvard University, and in particular Harvard Medical School in Boston, is globally recognized as a benchmark for excellence in biomedical research, clinical innovation, and translational medicine. In this highly prestigious scientific environment, Bioscience Institute is developing a collaborative partnership with Harvard Medical School to advance research and validation within its longevity protocol. The cooperation focuses on molecular markers, ageing pathways, and evidence-based strategies aimed at improving long-term health and biological resilience. This partnership reinforces our commitment to scientific rigor, international collaboration, and the continuous evolution of personalized longevity programs.